Asthma & Allergy Research Group, Centre of Cardiovascular and Lung Biology, University of Dundee, Dundee DD1 9SY, Scotland, United Kingdom.
Ann Allergy Asthma Immunol. 2012 Feb;108(2):77-80. doi: 10.1016/j.anai.2011.11.013.
Nasal blood flow (NBF) plays a crucial role in many physiological and pathological processes but its regulation and relation to other rhinological outcomes is poorly understood.
We measured nasal airway patency, nasal blood flow, and subjective and objective measures of decongestion and assessed their reproducibility and responsiveness.
19 healthy adults attended twice. A dose-response curve was constructed using doubling doses of oxymetazoline of 25 μg, 50 μg, 100 μg, and 200 μg at 20 minute intervals. Peak nasal inspiratory flow (PNIF) and nasal airway resistance (NAR) were measured at baseline and after each successive dose, NBF using laser Doppler flowmetry at baseline, 50 μg and 200 μg and a decongestion visual analogue scale after the final dose.
After the final dose of oxymetazoline, NBF decreased by a mean (95% CI, P value) of 139.6 (108.3-170.8, P < .001) units and 99.4 (68.1-130.7, P < .001) units, PNIF increased by 48.9 (22.0-75.8, P < .001) L.min-1 and 38.9 (12.0-65.8, P = .003) L.min-1, and NAR decreased by 0.1 (0.02-0.15, P < .001) Pa/s/cm(3) and 0.09 (0.02-0.15, P = .002) Pa.s.cm-3 at the first and second visits respectively. The area under the curve of decongestion was not significantly different between visits for each variable. The standardized response means for the decongestant response were as follows: NBF, 1.41; PNIF, 1.03; and NAR, 0.97.
Nasal blood flow using laser Doppler flowmetry is a sensitive and reproducible outcome to decongestion with oxymetazoline, similar to nasal patency and symptoms.
www.clinicaltrials.gov (NCT 00487032).
鼻血流（NBF）在许多生理和病理过程中起着至关重要的作用，但它的调节及其与其他鼻科学结果的关系还知之甚少。
我们测量了鼻气道通畅度、鼻血流量以及主观和客观的减充血测量值，并评估了它们的可重复性和反应性。
19 名健康成年人参加了两次试验。使用倍他米松 25μg、50μg、100μg 和 200μg 的 20 分钟间隔剂量反应曲线，测量峰值鼻吸气流量（PNIF）和鼻气道阻力（NAR）在基线和每个连续剂量后的测量值，使用激光多普勒血流仪在基线、50μg 和 200μg 时测量 NBF，并在最后一次给药后测量减充血视觉模拟评分。
在最后一次使用倍他米松后，NBF 平均下降 139.6（95%CI，P 值<.001）和 99.4（68.1-130.7，P<.001）单位，PNIF 增加 48.9（22.0-75.8，P<.001）和 38.9（12.0-65.8，P=.003）L.min-1，NAR 分别降低 0.1（0.02-0.15，P<.001）和 0.09（0.02-0.15，P=.002）Pa.s/cm3，在第一次和第二次就诊时分别为 0.1（0.02-0.15，P<.001）和 0.09（0.02-0.15，P=.002）Pa.s.cm-3。在每次就诊时，各变量的减充血曲线下面积无显著差异。倍他米松的减充血反应的标准化反应均值如下：NBF，1.41；PNIF，1.03；和 NAR，0.97。
使用激光多普勒血流仪测量的鼻血流是一种对倍他米松减充血敏感且可重复的结果，与鼻通气和症状相似。
www.clinicaltrials.gov（NCT 00487032）。
Zotero 插件